Franziska Poetzinger

Learn More
first-line therapy. Randomized studies have compared imatinib with nilotinib, dasatinib or bosutinib. None of these studies showed a significant survival difference, although SGTKIs enabled faster attainment of CCyR, deeper molecular remissions and fewer disease progressions. More importantly, none of the aforementioned studies compared their new drug with(More)
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive and heterogeneous disease. The diagnosis is predominantly based on immunophenotyping. In addition to known cytogenetic abnormalities molecular mutations were recently identified. Here, 90 adult T-ALL cases were investigated for mutations in NOTCH1, FBXW7, PHF6, CDKN2A, DNMT3A, FLT3, PTEN, and(More)
(P1⁄4 .009). In all four groups, the majority of deaths were due to B-cell lymphoma/leukemia. We had hypothesized that irradiation would accelerate the development of disease in at least some of the recipient animals. Although there was substantial overlap of the survival curves of genetically matched irradiated and unirradiated groups, the survival curves(More)
Chromosomal translocations of the MLL H3K4 histone methyltransferase gene on chromosome 11q23 are associated with unique subsets of both acute lymphoblastic (ALL) and acute myeloid leukemias (AML). The MLL gene encodes for a large protein of 3969 amino acids and has a role in chromatin-mediated transcriptional regulation. Translocations of chromosome 11q23(More)
  • 1